Skip to content

News and
Events

Sort By
  • Newest
  • Oldest
  • A to Z
  • Z to A
Feb 28 2020
Graybug Vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American Glaucoma Society Annual Meeting
REDWOOD CITY, Calif., February 28, 2020 – Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today presented pre-clinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up...
Read More
Oct 2 2019
Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration
Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the initiation of its Phase 2b study (ALTISSIMO) with GB-102 in...
Read More
Sep 18 2019
Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion
Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the initiation of its Phase 2a study with GB-102 in patients...
Read More
Aug 20 2019
Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs
Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million Series C financing. Proceeds from...
Read More
Feb 5 2019
Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis
Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative therapies for ocular diseases, today announced that the Board of Directors has appointed Frédéric Guerard as Chief Executive Officer. Mr. Guerard’s career in the pharmaceutical industry spans over 20 years and includes multiple leadership, strategic, and commercial roles.  He...
Read More
Jan 21 2019
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019
ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) • Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment of wet AMD • GB-102 was well-tolerated with no dose limiting...
Read More
1 2 3 5 6